Analysts: Buy the Pullback on This Chip Stock

Analysts think NVDA stock is a buying opportunity after last week's earnings drop

Managing Editor
Aug 14, 2017 at 10:27 AM
facebook twitter linkedin


Analysts are weighing in on electric car manufacturer Tesla Inc (NASDAQ:TSLA), chip concern NVIDIA Corporation (NASDAQ:NVDA), and biotech stock Soligenix, Inc. (NASDAQ:SNGX). Here's a quick roundup of today's bullish brokerage notes on shares of TSLA, NVDA, and SNGX.

Price-Target Hikes Help Tesla Stock Charge Higher

Tesla stock is up 2.6% to trade at $367.03, after Baird and Morgan Stanley raised their price targets on the stock, to $411 -- in uncharted territory -- and $317, respectively. The analysts waxed optimistic on the potential of the Model 3, with Morgan Stanley upping its volume and production estimates. Meanwhile, Tesla last week raised a bigger-than-expected $1.8 billion in its first junk-bond offering

TSLA stock has more than doubled in the past nine months, with recent pullbacks contained by its 100-day moving average. The shares are now back within striking distance of their June 23 all-time high of $386.99. Options traders have been call-skewed on TSLA for some time now. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day call/put volume ratio of 1.16 ranks in the 79th percentile of its annual range.

Canaccord Genuity: Buy the NVDA Pullback

NVIDIA stock is up 3.5% to trade at $161.45, after Canaccord Genuity raised its price target to $190 from $180. Specifically, the analysts  said traders should buy the earnings pullback, which could "prove the entry point many investors have been looking for." Despite the short-term struggles, NVDA stock has tacked on over 155% year-over-year, and touched a new record high of $174.56 last Tuesday. 

However, there some analysts who remain skeptical. Of the 27 brokerages covering NVDA, 11 rate it a "hold" or worse. This means there is plenty of room for upgrades that could push NVDA stock to new heights, should the equity resume its quest for all-time highs. 

Increased Funding, Price-Target Hikes Boost SNGX

Soligenix stock is up 4.7% at $2.15, after the company said it received additional NIAID  funding for the development of its Ricin vaccine. In addition, SNGX stock received a price-target hike to $5 from $4 at Maxim Group. It's been a sluggish year for SNGX, which has lost 67% year-over-year, with rally attempts stalling at the equity's 200-day moving average. Analysts see something they like, however, as all three brokerages covering Soligenix shares rate them a "strong buy."
 
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners